WASHINGTON — The Food and Drug Administration is in a precarious position as it heads toward 2026.
The agency has been mired by high-profile departures, feuds between top leaders, accusations of politicization, and low morale. It has lost thousands of employees to layoffs and resignations and cannot seem to hold onto a director of the drug center, which has been led by five different people since January.
Even the fate of Commissioner Marty Makary is up in the air. The personnel turmoil has caused concern among Health and Human Services and White House officials, according to Politico and The Wall Street Journal. These officials reportedly considered scaling back Makary’s responsibilities.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
